T-lymphocyte surface antigens (CD2, CD3, CD4, CD5, CD6, CD8, CD25, CD28, CD45, HLA class I) (ATG targets)

This target profile represents a composite group of T-lymphocyte surface antigens, including CD2, CD3, CD4, CD5, CD6, CD8, CD25, CD28, CD45, and HLA class I molecules, which are collectively targeted by polyclonal antithymocyte globulin (ATG) preparations (StatPearls, NBK538234). These proteins play diverse and essential roles in the immune system: CD3, CD4, and CD8 are central to the T-cell receptor (TCR) complex and antigen recognition; CD2, CD5, CD6, and CD28 serve as critical costimulatory and adhesion molecules; CD25 is the alpha chain of the IL-2 receptor indicating cell activation; and CD45 is a tyrosine phosphatase that regulates signaling (UniProt P08575, P07766). HLA class I molecules are vital for presenting endogenous peptides to CD8+ T-cells (PubMed, 1563488). In clinical practice, targeting this broad array of markers allows for the rapid depletion of circulating T-cells and the modulation of their function, which is a cornerstone in preventing and treating acute cellular rejection in organ transplantation and managing severe aplastic anemia or graft-versus-host disease (GVHD) (NIH, Thymoglobulin Label). The therapeutic effect is achieved through multiple pathways, including complement-mediated lysis, opsonization leading to phagocytosis, and the induction of T-cell apoptosis (PubMed, 11592110).

Other names

Antithymocyte globulin targetsThymocyte antigensT-cell surface markers

Polyclonal antibodies bind to multiple T-cell surface receptors, inducing rapid T-cell depletion through complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and the induction of apoptosis; they also interfere with T-cell signaling, adhesion, and antigen recognition (StatPearls, NBK538234; PubMed, 11592110).